The Pharma Letter2d
Argenx and Zai Lab secure China approval for Vyvgart Hytrulo
Dutch firm Argenx Euronext: ARGX) and China’s Zai Lab (HKEX: 9688) have received an approval from the National Medical ...
Seeking Alpha2d
Argenx upgraded at Wolfe on myasthenia gravis dominance
Argenx (NASDAQ:ARGX) shares trended higher on Tuesday after Wolfe Research upgraded the Dutch biotech to Outperform from Peer ...
Pharmaceutical Technology3d
Zai Lab and argenx announce NMPA approval for sBLA for VYVGART Hytrulo
Zai Lab and argenx have announced receipt of approval from the National Medical Products Administration (NMPA) of China for ...
Argenx upgraded to Outperform from Peer Perform at Wolfe Research
Wolfe Research upgraded Argenx (ARGX) to Outperform from Peer Perform with a $697 price target Now through 2025, there will be few exciting ...
Zai Lab, argenx Take in China Nod
Zai Lab Limited (NASDAQ: ZLAB) and argenx (NASDAQ: ARGX) today announced that China’s National Medical Products Administration (NMPA) approved the supplemental Biologics License Application (sBLA) for ...
argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China
First and only NMPA-approved treatment for patients with CIDP in China Second VYVGART Hytrulo indication approved in China November 11, 2024 – ...
Yahoo Finance4d
Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
November 11, 2024--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & Nasdaq: ARGX) today announced that China’s National Medical Products Administration (NMPA) ...